肿瘤细胞治疗研究
英文原题：Isolated oral CD30(+)/CD4(+) CAR(+) T cell lymphoma in long-term remission after radiotherapy.
Isolated oral CD30(+)/CD4(+) CAR(+) T cell lymphoma in long-term remission after radiotherapy.
一例嵌合抗原受体（CAR）⁺CD30⁺/CD4⁺ T 细胞淋巴瘤（TCL）在以抗 CD19 CAR T 细胞为基础的 tisagenlecleucel（tisa-cel）治疗后 22 个月表现为单个口腔溃疡。
一例CAR阳性CD30阳性/CD4阳性T细胞淋巴瘤（TCL）表现为单发口腔溃疡，发生于患者接受抗CD19 CAR-T细胞疗法tisagenlecleucel（tisa-cel）治疗22个月后。该TCL检测到慢病毒整合于ANKHD1-EIF4EBP3、TET2功能丧失以及NTRK1拷贝数增加，提示与插入突变无关的遗传改变参与了淋巴瘤发生。患者接受放射治疗后已缓解2年。这是俄亥俄州立大学James综合癌症中心在288例接受CAR-T细胞治疗的患者中报告的唯一CAR阳性TCL病例。
A chimeric antigen receptor (CAR) + CD30 + /CD4 + T cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T cell-based therapy. The TCL showed lentiviral integration in ANKHD1-EIF4EBP3, loss of function of TET2, and NTRK1 copy number gain, suggesting that genetic alterations unrelated to insertional mutagenesis contributed to lymphomagenesis. The patient remains in remission 2 years after radiotherapy. This is the only CAR + TCL case reported at the Ohio State University James Comprehensive Cancer Center out of 288 patients treated with CAR-T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
